PILL:NYE-Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 8.64

Change

+0.40 (+4.85)%

Market Cap

N/A

Volume

0.16M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B..

+3.98 (+12.78%)

USD 11.53B
QLD ProShares Ultra QQQ

+4.80 (+5.11%)

USD 5.39B
FNGU MicroSectors FANG+ Index 3X Le..

+39.02 (+10.21%)

USD 5.13B
SSO ProShares Ultra S&P500

+2.94 (+3.42%)

USD 4.50B
UPRO ProShares UltraPro S&P500

+4.09 (+5.08%)

USD 3.53B
TECL Direxion Daily Technology Bull..

+6.52 (+8.36%)

USD 3.15B
LABU Direxion Daily S&P Biotech Bul..

+6.50 (+4.73%)

USD 0.94B
USD ProShares Ultra Semiconductors

+8.45 (+7.99%)

USD 0.86B
DPST Direxion Daily Regional Banks ..

+8.40 (+8.17%)

USD 0.77B
YINN Direxion Daily FTSE China Bull..

+2.27 (+10.41%)

USD 0.76B

ETFs Containing PILL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.48% 26% F 61% D-
Dividend Return 0.63% 46% F 14% F
Total Return 12.12% 26% F 55% F
Trailing 12 Months  
Capital Gain 12.06% 20% F 44% F
Dividend Return 1.13% 37% F 15% F
Total Return 13.20% 18% F 38% F
Trailing 5 Years  
Capital Gain -40.91% 28% F 12% F
Dividend Return 1.60% 26% F 4% F
Total Return -39.31% 25% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -2.84% 12% F 24% F
Dividend Return -2.37% 10% F 15% F
Total Return 0.47% 37% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 105.70% 36% F 7% C-
Risk Adjusted Return -2.24% 10% F 24% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.